NASDAQ:PHAS PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free PHAS Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume848,888 shsMarket Capitalization$3.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaSustainabilityStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaSustainability Get PhaseBio Pharmaceuticals alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Read More Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry PHAS Stock News HeadlinesDecember 14, 2023 | finance.yahoo.comVelia Therapeutics Appoints Michael York as Chief Business OfficerJune 5, 2023 | finance.yahoo.comAlcami Announces CEO TransitionApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.May 12, 2023 | marketwatch.com8-K: PhaseBio Pharmaceuticals IncMarch 31, 2023 | finanznachrichten.deAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsMarch 31, 2023 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finance.yahoo.comBioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 22, 2023 | marketwatch.comCardiomyopathy Medication Market Size and Forecast till 2031April 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.February 28, 2023 | marketwatch.comCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries DataJanuary 17, 2023 | benzinga.comSFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio PharmaceuticalsJanuary 5, 2023 | bizjournals.comBankruptcy court approves PhaseBio's $32.9M asset transfer dealNovember 8, 2022 | marketwatch.comBankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab AssetsNovember 4, 2022 | benzinga.comShort Volatility Alert: PhaseBio Pharmaceuticals, Inc.November 2, 2022 | msn.comWhy Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day SessionNovember 1, 2022 | msn.comWhy Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving PremarketOctober 27, 2022 | benzinga.comPhaseBio Pharmaceuticals 10% Owner Trades Company's StockOctober 25, 2022 | wsj.comPhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s LawsuitOctober 25, 2022 | bizjournals.comPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100MOctober 24, 2022 | nasdaq.comPhaseBio Pharma Files For Chapter 11 Bankruptcy ProtectionOctober 24, 2022 | finance.yahoo.comPhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy CodeOctober 24, 2022 | finance.yahoo.comPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $60MOctober 24, 2022 | finance.yahoo.comPhaseBio Files for Bankruptcy With Plans to Sell AssetsOctober 19, 2022 | bizjournals.comCash-strapped PhaseBio sued by drug development partner in dispute over experimental therapyOctober 6, 2022 | finance.yahoo.comPhaseBio Might Have To Return Global Rights To Its Lead ProgramOctober 3, 2022 | finance.yahoo.comHypertension Clinical Trials Pipeline Analysis: 90+ Companies are Working to Improve the Treatment Space | DelveInsightSeptember 29, 2022 | finance.yahoo.comWhy an East Bay company wants control of its partner's blood thinner antidoteSee More Headlines Receive PHAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHAS CUSIPN/A CIK1169245 Webwww.phasebio.com Phone(610) 981-6500FaxN/AEmployees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,070,000.00 Net Margins-12,572.13% Pretax Margin-12,572.13% Return on EquityN/A Return on Assets-174.38% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.47 Sales & Book Value Annual Sales$818,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.93) per share Price / BookN/AMiscellaneous Outstanding Shares49,858,000Free Float44,922,000Market Cap$3.50 million OptionableNot Optionable Beta2.57 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesJonathan P. MowChief Executive Officer & DirectorJohn P. SharpChief Financial OfficerJohn S. LeeChief Medical OfficerKristopher L. HansonSecretary, Senior VP & General CounselSusan E. ArnoldSenior Vice President-Technical OperationsKey CompetitorsGeoVax LabsNASDAQ:GOVXAridis PharmaceuticalsNASDAQ:ARDSNexImmuneNASDAQ:NEXIMustang BioNASDAQ:MBIOAtrecaNASDAQ:BCELView All Competitors PHAS Stock Analysis - Frequently Asked Questions How were PhaseBio Pharmaceuticals' earnings last quarter? PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The business earned $0.34 million during the quarter, compared to the consensus estimate of $2.67 million. What other stocks do shareholders of PhaseBio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX). When did PhaseBio Pharmaceuticals IPO? PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager. How do I buy shares of PhaseBio Pharmaceuticals? Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHAS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PhaseBio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
